Swaminathan P. Iyer, MD, of the University of Texas MD Anderson Cancer Center, explains the mechanism of action and efficacy/safety observed in phase 1 results of CTX130, a CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy, in the treatment of relapsed/refractory T-cell lymphoma.
Watch
Survivors of Childhood Cancer More Likely to Be Undertreated for CVD Risk Factors
June 11th 2022Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.
Read More
AI Holds Potential to Support Ethical Principles in Hematology—but There’s a Dark Side
June 11th 2022During a session at the 2022 European Hematology Association Congress, speakers discussed how artificial intelligence (AI) can help advance the principles of ethical medicine—but also how new technologies are being used to undermine the integrity of scientific research.
Read More
ALPINE, SEQUOIA Findings: Zanubrutinib Offers Improved HRQOL in CLL/SLL
June 11th 2022Abstracts presented at the 2022 European Hematology Association Congress demonstrate superior health-related quality of life (HRQOL) outcomes among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) taking zanubrutinib.
Read More
Study Examines T1D Eating Patterns of Youth After COVID-19 Lockdowns in Italy
June 10th 2022Findings of a study on children and adolescents with type 1 diabetes (T1D) in Italy suggest lockdown periods during COVID-19 did not increase disordered eating symptoms or adversely affect disease management.
Read More
Dr Ravi Parikh Offers Solutions to Barriers During Shift From Fee-for-Service to APMs
June 10th 2022Designing rational spending targets and having small sample sizes are 2 main challenges payers and partners face in the shift toward alternative payment models (APMs), said Ravi B. Parikh, MD, MPP, assistant professor of medical ethics and health policy, assistant professor of medicine, University of Pennsylvania.
Watch
Dr Constantine Tam Discusses Impact of Public Funding for BTK Inhibitor Use in R/R CLL
June 10th 2022Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, explains findings of his abstract at EHA2022 showing the impact of Australia’s pharmaceuticals benefit scheme on the rise of Bruton tyrosine kinase (BTK) inhibitor prescriptions for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as well as reasons behind the decrease in fludarabine, cyclophosphamide, and rituximab combination therapy usage for first-line CLL.
Watch
Abstracts Demonstrate Long-term, Real-world Advantages of Zanubrutinib in WM
June 10th 2022In abstracts featured at the 2022 European Hematology Association Congress, investigators detailed long-term results of the ASPEN phase 3 trial and an expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM).
Read More
Dr Patricia Deverka Addresses Potential Disparities in Multicancer Early Detection Tests
June 10th 2022Providing insurance coverage for multicancer early detection (MCED) tests is vital to reduce disparities in access, said Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco.
Watch
GlaxoSmithKline (GSK) aims to have its respiratory syncytial virus (RSV) vaccine reviewed later this year; Northwell Health and Kaiser Permanente among CEOs supporting gun legislation; Infants whose mothers had COVID-19 during their pregnancy had double the risk of delayed speech or motor skills.
Read More
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center and University of Washington, discussed positive health-related quality of life (HRQOL) findings of the SEQUOIA trial investigating zanubrutinib vs bendamustine/rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Watch
Genetics, Immunophenotyping Help Drive CLL Treatment Selection, but More Knowledge Needed
June 10th 2022An education session at the 2022 European Hematology Association Congress featured updates on using genetic and immune characteristics to select the optimal treatment pathway in chronic lymphocytic leukemia (CLL).
Read More
Combining Techniques Boosts Diagnostic Sensitivity in Intrahepatic Cholangiocarcinoma
June 9th 2022Hepatobiliary-phase enhanced imaging outperformed diffusion-weighted imaging in distinguishing intrahepatic mass-forming cholangiocarcinoma, but the accuracy is greater when these methods are used in tandem.
Read More